Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood pressure drug aims for Round-the-Clock control

NCT ID NCT06174766

Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This clinical trial is testing a new medication called HGP2102 for people with essential hypertension, or high blood pressure. The study compares HGP2102 to a control drug to see how well it lowers blood pressure over a full 24-hour period. Participants are adults with high blood pressure who meet specific blood pressure criteria. The goal is to determine if HGP2102 is safe and effective for managing this common condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HGP2102
What this could lead to
If successful, HGP2102 could offer a new treatment option for people with high blood pressure, potentially improving blood pressure control.
What could go wrong
This is a phase 3 trial, so while promising, the drug may not prove more effective than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

356 people

The number who actually took part.

Started

May 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects whose clinic blood pressure measured in visit 1 corresponds to the following conditions * sitSBP \< 180 mmHg and sitDBP \< 110mg for patients receiving any BP-lowering drug within 1 month prior to Visit 1 * 140mmHg ≤ sitSBP \< 180mmHg and 60mmHg ≤ sitDBP \< 110mmHg 2. Subjects whose clinic and ambulatory blood pressure measured in visit 2 corresponds to the following conditions * 24h-ABPM: 130mmHg ≤ SBP \< 170mmHg * clinic BP: 140 mmHg ≤ sitSBP \< 180 mmHg and 60 mmHg ≤ sitDBP \< 110 mmHg Exclusion Criteria: 1. Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1 2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1 3. Orthostatic hypotension with symptoms within 3 months prior to visit 1 4. Secondary hypertension patient or suspected to be 5. Uncontrolled type II diabetes mellitus (HbA1c \> 9%) or type I diabetes mellitus 6. Severe heart disease or severe neurovascular disease 7. Moderate or malignant retinopathy 8. Severe renal diseases (eGFR\<30mL/min/1.73m2) 9. Severe or active hepatopathy (AST or ALT ≥ 2 times of normal range) 10. Hypokalemia or Hyperkalemia (K\<3.5mmol/L or K ≥ 5.5mmol/L) 11. Hyponatremia or Hypernatremia (Na\<135mmol/L or Na ≥ 155mmol/L) 12. History of malignancy tumor 13. History of alcohol or drug abuse 14. Positive to pregnancy test, nursing mother, intention on pregnancy 15. Considered by investigator as not appropriate to participate in the clinical study with other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Severance hosptal

    Seodaemun-gu, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.